Imatinib (400 mg/day) versus imatinib (600 mg/day) in patients with advanced GIST
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 06 Jun 2017 Results of a genomic analysis presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Nov 2010 New trial record.